« Return to News | Drug Sponsors

Ambit completes $25M financing for AML drug

Wednesday, November 7, 2012 10:36 AM

Ambit Biosciences, a privately held biopharmaceutical company based in San Diego, has closed the first $25 million tranche of a new $50 million preferred stock financing to support continued advancement of its lead drug candidate, quizartinib, for the treatment of acute myeloid leukemia (AML).

Existing investor OrbiMed Advisors led the financing with participation from other existing Ambit investors including Aisling Capital, Apposite Healthcare, Roche Ventures, GrowthWorks, MedImmune Ventures, Forward Ventures, GIMV and Radius Ventures.

"2012 has been a pivotal year of progress for Ambit, and this financing is a reflection of that progress and the momentum we have built as a team. We've received the data from our large, 333-patient phase II trial of quizartinib in patients with relapsed/refractory AML,” said Michael Martino, president and CEO of Ambit. “We've refocused and prioritized our work on earlier stage pipeline assets, including our oral JAK2 and CSF1R inhibitor programs, and re-energized the team. This financing, with OrbiMed Advisors leading a round in which all existing investors participated, is a strong vote of confidence in our direction and provides the resources to accelerate our progress in 2013.”

In conjunction with the financing, David Bonita, M.D, of OrbiMed Advisors will join Ambit's board of directors.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.